JAK inhibitor compound and crystal form

By developing a new JAK inhibitor compound and its crystal form, the problems of low water and fat solubility of tofatinib were solved, and better drug preparation design was achieved to effectively prevent and treat rashes caused by anti-tumor agents and Skin disease.

WO2024235149A1PCT designated stage expired Publication Date: 2024-11-21ONQUALITY PHARMA (CHINA) LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/092575
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-05-11
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

The existing tofatinib has problems of low water and fat solubility in clinical applications, which leads to difficulties in the development of skin preparations. It is urgent to develop new JAK inhibitor prodrugs to solve this problem.

Method used

Provide a new compound and its crystal form, which is identified by X-ray powder diffraction and differential scanning calorimetry testing. It has good stability and high purity, suitable for production and preservation, and can be used for the preparation of drugs. Compositions are used to improve water solubility and fat solubility.

Benefits of technology

Achieve improvement of the water and fat solubility of the compounds, provide better drug preparation design, solve the shortcomings of existing tofatinib in the development of skin preparations, and effectively prevent and treat rashes and other skin diseases caused by anti-tumor agents. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024092575-FTAPPB-I100001
    Figure PCTCN2024092575-FTAPPB-I100001
  • Figure PCTCN2024092575-FTAPPB-I100002
    Figure PCTCN2024092575-FTAPPB-I100002
  • Figure PCTCN2024092575-FTAPPB-I100003
    Figure PCTCN2024092575-FTAPPB-I100003
Patent Text Reader

Abstract

The present application relates to a compound or a crystal form thereof, a preparation method and use thereof, and a pharmaceutical composition containing the compound or the crystal form thereof. The compound or the pharmaceutical composition is used as a JAK inhibitor prodrug, and the JAK inhibitor may comprise tofacitinib.
Need to check novelty before this filing date? Find Prior Art

Description

JAK inhibitor compounds and crystal forms Technical Field

[0001] The present application relates to the field of biomedicine, and specifically to a compound and its crystal form. The compound can be used as a prodrug of a JAK inhibitor. The present application also relates to the use of the compound or its crystal form. Background Art

[0002] Tofacitinib is a JAK inhibitor that effectively inhibits the activity of JAK1 and JAK3. Existing studies have shown that tofacitinib has a positive therapeutic effect on a variety of inflammatory diseases, including rheumatoid arthritis, ulcerative colitis, and psoriasis. On the other hand, prior art also discloses side effects associated with the use of tofacitinib in treating certain anti-tumor agents. However, existing tofacitinib has several drawbacks in clinical application: its low water and lipid solubility makes it unsuitable for the development of skin preparations.

[0003] Therefore, there is an urgent need to develop new compounds to solve the problems of the existing tofacitinib and to meet the medication needs in current formulation development.

[0004] Summary of the Invention

[0005] The present application provides a new compound that can be used as a prodrug of a JAK inhibitor. The present application also relates to a crystalline form of the compound. The crystalline forms of the different compounds prepared in the present application can be identified and distinguished from other crystalline forms by means of their characteristic X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) curves, and the like. The compounds or crystalline forms provided in the present application have good stability, high purity, good crystallinity, and are suitable for production and storage.

[0006] In one aspect, the present application provides a compound of formula (I), the structural formula of which is:

[0007] In certain embodiments, the compound of formula (I) includes its crystalline form, pharmaceutically acceptable salt, biologically active metabolite, solvate, hydrate, racemate, enantiomer or stereoisomer.

[0008] On the other hand, the present application also provides a crystalline form A of the compound of formula (I),

[0009] In the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 8.2±0.2° and 11.3±0.2°.

[0010] In certain embodiments, the crystalline form A of the compound of formula (I) further exhibits characteristic peaks at at least one of the 2θ angles of 6.8±0.2°, 15.7±0.2°, 17.0±0.2°, 17.6±0.2°, 19.6±0.2°, 20.6±0.2°, 21.2±0.2°, 23.9±0.2° and 24.7±0.2°.

[0011] On the other hand, the present application also provides a crystalline form A of the compound of formula (I),

[0012] It has an endothermic peak at 120.7±1°C.

[0013] On the other hand, the present application also provides a crystalline form B of the compound of formula (I),

[0014] In the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 7.0±0.2°, 7.8±0.2° and 21.1±0.2°.

[0015] In certain embodiments, the crystalline form B of the compound of formula (I) further exhibits characteristic peaks at at least one of the 2θ angles of 14.0±0.2°, 11.2±0.2°, 19.6±0.2°, 17.5±0.2°, 28.2±0.2°, 20.5±0.2°, 26.2±0.2°, 20.9±0.2° and 19.8±0.2°.

[0016] On the other hand, the present application also provides a crystalline form B of the compound of formula (I),

[0017] It has endothermic peaks at 95.1±1°C and 113.4±1°C.

[0018] On the other hand, the present application also provides a pharmaceutical composition, which includes the compound of formula (I), the crystalline form A of the compound of formula (I), the crystalline form B of the compound of formula (I), and optionally a pharmaceutically acceptable carrier.

[0019] On the other hand, the present application also provides the compound of formula (I), the crystalline form A of the compound of formula (I), the crystalline form B of the compound of formula (I), or the use of the pharmaceutical composition as a JAK inhibitor prodrug.

[0020] On the other hand, the present application also provides the compound of formula (I), the crystalline form A of the compound of formula (I), the crystalline form B of the compound of formula (I), or the use of the pharmaceutical composition in the preparation of a drug, which is used to prevent and / or treat diseases and / or conditions.

[0021] In certain embodiments, the disease and / or condition comprises a disease or condition associated with an anti-tumor agent in a subject.

[0022] In certain embodiments, the disease or disorder associated with an anti-tumor agent comprises a rash associated with administration of an anti-tumor agent.

[0023] In certain embodiments, the disease and / or condition comprises a disease or condition of the skin and / or a disease or condition of the subcutaneous tissue.

[0024] In certain embodiments, the skin disease or disorder comprises an immune skin disease or disorder.

[0025] In certain embodiments, the skin disease or condition comprises atopic dermatitis, alopecia areata, or psoriasis.

[0026] In certain embodiments, the drug is administered in a form comprising a cream, lotion, gel, ointment, salves, spray, liposomal formulation, liniment, and / or aerosol.

[0027] In certain embodiments, the medicament further comprises one or more other active ingredients.

[0028] On the other hand, the present application also provides a method for preventing and / or treating diseases and / or conditions, which comprises administering the compound of formula (I), the crystalline form A of the compound of formula (I), the crystalline form B of the compound of formula (I), or the pharmaceutical composition to a subject in need.

[0029] In certain embodiments, the disease and / or condition comprises a disease or condition associated with an anti-tumor agent in a subject.

[0030] In certain embodiments, the disease or disorder associated with an anti-tumor agent comprises a rash associated with administration of an anti-tumor agent.

[0031] In certain embodiments, the disease and / or condition comprises a disease or condition of the skin and / or a disease or condition of the subcutaneous tissue.

[0032] In certain embodiments, the skin disease or disorder comprises an immune skin disease or disorder.

[0033] In certain embodiments, the skin disease or condition comprises atopic dermatitis, alopecia areata, or psoriasis.

[0034] On the other hand, the present application also provides a drug combination or kit comprising: 1) an anti-tumor agent; and 2) the compound of formula (I), the crystalline form A of the compound of formula (I), the crystalline form B of the compound of formula (I) or the pharmaceutical composition.

[0035] In certain embodiments, the pharmaceutical combination or kit further comprises a buffer.

[0036] In certain embodiments, the pharmaceutical combination or kit further comprises an excipient.

[0037] In certain embodiments, the component 1) and the component 2) in the pharmaceutical combination or kit are not mixed with each other.

[0038] Those skilled in the art can easily discern other aspects and advantages of the present application from the detailed description below. In the detailed description below, only exemplary embodiments of the present application are shown and described. As will be appreciated by those skilled in the art, the content of this application enables those skilled in the art to modify the disclosed specific embodiments without departing from the spirit and scope of the invention to which this application relates. Accordingly, the descriptions in the drawings and specification of this application are merely exemplary and not restrictive. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] The specific features of the inventions of this application are set forth in the appended claims. The features and advantages of the inventions of this application can be better understood by referring to the exemplary embodiments described in detail below and the accompanying drawings. A brief description of the drawings is as follows:

[0040] FIG1 shows the XPRD spectrum of the Form A crystal form of the compound of formula (I) described in the present application.

[0041] FIG2 shows the DSC spectrum of the Form A crystal form of the compound of formula (I) described in the present application.

[0042] FIG3 shows the XPRD spectrum of the Form B crystalline form of the compound of formula (I) described in the present application.

[0043] FIG4 shows the DSC spectrum of the Form B crystal form of the compound of formula (I) described in the present application.

[0044] FIG5 shows photographs of the left side, back, and right side of a rat with a rash induced by the targeted therapeutic agent described in the present application.

[0045] Figure 6 shows representative photos of the rashes of rats in the control group and the drug-treated group in Examples 3-27 of the present application.

[0046] FIG7 shows the rash grade results of some control groups and drug-treated groups in Examples 3-27 of the present application.

[0047] FIG8 shows the rash grade results of some control groups and drug-treated groups in Examples 28-30 of the present application.

[0048] FIG9 shows the rash grade results of some control groups and drug-treated groups in Examples 31-44 of the present application.

[0049] FIG10 shows the rash grade results of some control groups and drug-treated groups in Examples 45-48 of the present application. DETAILED DESCRIPTION

[0050] The following describes the implementation of the present invention through specific embodiments. Those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.

[0051] Definition of terms

[0052] In this application, the terms "crystal form", "polymorph", "polymorphs", "crystal modification", "crystalline modification", "polymorphic form" and "crystalline form" are understood to be synonymous and generally refer to solid crystalline forms of a compound or complex, including but not limited to single-component or multi-component crystals, and / or polymorphs, solvates, hydrates, clathrates, co-crystals, salts, solvates of salts, and hydrates of salts of a compound.

[0053] Polymorphs can be detected, identified, classified, and characterized using techniques well known to those skilled in the art, such as, but not limited to, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), X-ray powder diffraction (XRPD), single crystal X-ray diffraction, vibrational spectroscopy, solution calorimetry, solid-state nuclear magnetic resonance (SSNMR), Fourier transform infrared spectroscopy (FT-IR spectroscopy), Raman spectroscopy, hot stage optical microscopy, scanning electron microscopy (SEM), electron crystallography, as well as quantitative analysis, particle size analysis (PSA), surface area analysis, solubility, and dissolution rate. Polymorphism can be described as the ability of a particular compound to crystallize in different crystalline variations while maintaining the same chemical formula. Polymorphs of a given substance are chemically identical, containing the same atoms bonded to each other in the same manner, but differing in their crystalline variations, which can affect one or more physical properties, such as dissolution rate, melting point, bulk density, stability, flow properties, and the like. Small variations in the graphical representation of such data (e.g., peak relative intensities and peak positions) may occur due to factors such as variations in instrument response and variations in sample concentration and purity, as is well known to those skilled in the art. Nevertheless, one skilled in the art would be able to compare the graphical data in the figures of this application with graphical data generated for an unknown crystal form and determine whether the two sets of graphical data represent the same crystal form.

[0054] Unless otherwise indicated, when referring to spectra or data presented in graphical form (e.g., XRPD, FT-IR, and NMR spectra), the term "peak" generally refers to a peak or other distinctive feature that is not due to background noise and that can be identified by one of ordinary skill in the art.

[0055] As is well known in the art of X-ray powder diffraction (XRPD), for any given crystalline form, the apparatus used to obtain the X-ray powder diffraction pattern, humidity, temperature, orientation of the powder crystals, and other parameters may all result in some variability in the appearance, intensity, and position of the peaks in the diffraction pattern. See, for example, The United States Pharmacopeia #23, National Formulary #18, pp. 1843-1844, 1995. In the present case, the variability of the peak position of ±0.2° 2θ takes into account these possible variations without hindering the unambiguous identification of the crystalline form shown. The identification of a crystalline form can be based on any unique differential peak (in ° 2θ units) or a combination thereof, typically the more prominent peak. Thus, in some embodiments, the crystalline compound of the present application is characterized by an XRPD pattern having certain peak positions having substantially the same characteristics as the XRPD pattern provided in the accompanying drawings of the present application. Depending on the instrumentation used in the present application, the diffraction peak positions may have an error tolerance of ±0.2°. For example, an X-ray powder diffraction pattern that is "substantially consistent" with FIG. 1 provided herein may be the same as the XRPD pattern in the accompanying drawings, or more likely it may be slightly different. Such an XRPD pattern may not necessarily show every peak in the diffraction pattern presented herein, and / or may show slight changes in the appearance, intensity, or displacement of the peaks due to differences in the conditions involved in obtaining the data. A person skilled in the art can determine whether a sample of a crystalline compound has the same crystalline form as the crystalline form disclosed herein or a different crystalline form by comparing their XRPD patterns. Similarly, a person skilled in the art can determine whether a given diffraction peak position (expressed in ° 2θ) obtained from an XRPD pattern is in approximately the same position as the numerical value presented herein. In the context of the present application, the 2θ values ​​in the X-ray powder diffraction patterns are all in degrees (°).

[0056] Similarly, as is well known in the field of differential scanning calorimetry (DSC), the melting peak height of a DSC curve depends on many relevant factors, such as sample preparation and test instrument conditions, while the peak position is relatively insensitive to experimental details. Therefore, in some embodiments, the crystalline compound of the present application is characterized by a DSC graph with a characteristic peak position, having substantially the same properties as the DSC graph provided in the accompanying drawings of the present application. Depending on the instrument conditions used in this test, the melting temperature has an error tolerance of ±3°C, ±4°C, or ±5°C.

[0057] "Substantially the same" or "essentially the same" as an X-ray powder diffraction pattern or a DSC graph generally means that at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or at least about 95%, or at least about 99% of the peaks in the X-ray powder diffraction pattern or the DSC graph are shown in the graph.

[0058] The purity of the crystals of the present application can be determined by, for example, known methods such as X-ray powder diffraction, thermal analysis, etc. The purity of the crystals or mixed crystals of the present application does not need to be 100%, and can be not less than about 60%, not less than about 70%, or not less than about 80%, or not less than about 90%, or not less than about 95%, or not less than about 98%. Purity within this range can ensure quality.

[0059] The terms "about" and "approximately" as used herein generally refer to within ±10%, suitably within ±5%, and particularly within ±1% of a given value or range. Alternatively, to one of ordinary skill in the art, the terms "about" and "approximately" generally mean within an acceptable standard error of the mean.

[0060] The term "pharmaceutical composition" generally refers to a mixture of one or more compounds described herein, or physiologically / pharmaceutically acceptable salts or prodrugs thereof, with other chemical components, such as physiologically / pharmaceutically acceptable excipients, vehicles, diluents, adjuvants, vehicles, and additional therapeutic agents. The purpose of a pharmaceutical composition is to facilitate administration of the compound to an organism.

[0061] As described herein, the pharmaceutically acceptable compositions of the present invention may further comprise pharmaceutically acceptable excipients, such as those used herein, including any solvent, solid excipient, diluent, binder, disintegrant, or other liquid excipient, dispersant, flavoring or suspending agent, surfactant, isotonic agent, thickener, emulsifier, preservative, solid binder or lubricant, etc., suitable for the specific target dosage form. The following references describe: I n Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. D. B. Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York. The contents of these references indicate that various excipients can be used in the preparation of pharmaceutically acceptable compositions and their known preparation methods. Except to the extent that any conventional excipients are incompatible with the compounds of the present application, such as by producing any adverse biological effects or interacting in a deleterious manner with any other components of the pharmaceutically acceptable composition, their use is also contemplated by the present application.

[0062] Detailed Description of the Invention

[0063] Compound and its crystal form, pharmaceutical composition, drug combination or kit

[0064] In one aspect, the present application provides a compound comprising a structure shown in formula (I) (compound of formula (I)),

[0065] In the present application, the compounds may also include analogs of the compounds of formula (I). For example, the structure of the compound may be obtained by replacing substituents in the structure of formula (I). For example, the replacement of the substituents may be conventional replacements well known to those skilled in the art. For example, after the replacement of the substituents, those skilled in the art can still expect that the new compound structure can have similar or similar technical effects as the compound of formula (I) described in the present application.

[0066] In this application, the term "Formula (I)" may be referred to as "compound of Formula (I)", "compound of Formula (I)". Such terms are also defined to include all forms of the compound of Formula (I), including hydrates, solvates, isomers, crystalline and non-crystalline forms, isomorphs, polymorphs and metabolites. For example, the compound of Formula (I) or a pharmaceutically acceptable salt thereof may exist in both unsolvated and solvated forms. When the binding force of the solvent or water is strong, the complex has a well-defined stoichiometry that is not affected by humidity. However, when the binding force of the solvent or water is weak, such as in channel solvates and hygroscopic compounds, the water / solvent content will depend on humidity and drying conditions, in which case non-stoichiometry is the norm.

[0067] "Compounds of formula (I)" may have asymmetric carbon atoms. In this application, carbon-carbon bonds of compounds of formula (I) may be represented by solid lines, solid wedges, or dotted wedges. The use of solid lines to depict bonds to asymmetric carbon atoms indicates that all possible stereoisomers at that carbon atom are included (e.g., specific enantiomers, racemic mixtures, etc.). The compounds of the present application may contain more than one asymmetric carbon atom. In these compounds, the use of solid lines to represent bonds to asymmetric carbon atoms is intended to indicate that all possible stereoisomers should be included. For example, unless otherwise indicated, it is intended that compounds of formula (I) may exist as enantiomers and diastereomers or as racemates and mixtures. The use of solid lines to depict bonds to one or more asymmetric carbon atoms in compounds of formula (I), and the use of solid or dotted wedges to describe bonds to other asymmetric carbon atoms in the same compound, indicates the presence of a mixture of diastereomers.

[0068] The compounds of the present application may exist in the form of inclusion compounds or other complexes. Included within the scope of the present invention are complexes, such as inclusion compounds, drug-host inclusion complexes, wherein, in contrast to the above-mentioned solvates, the drug and host are present in stoichiometric or non-stoichiometric amounts. Also included are complexes of formula (I) containing two or more organic and / or inorganic components that may be stoichiometric or non-stoichiometric. The resulting complex may be ionized, partially ionized, or non-ionized.

[0069] Stereoisomers of formula (I) include cis and trans isomers, optical isomers, such as R and S enantiomers, diastereomers, geometric isomers, rotational isomers, conformational isomers and tautomers, compounds of formula (I), including compounds that exhibit more than one type of isomerism; and mixtures thereof (e.g., racemates and diastereomeric pairs). Also included are acid addition salts or base addition salts in which the counterion is optically active, such as D-lactate or L-lysine, or racemates, such as DL-tartrate or DL-arginine.

[0070] When any racemate crystallizes, two different types of crystals are possible. The first type is the racemic compound described above (a true racemate), in which one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts. The second type is a racemic mixture or conglomerate, in which two forms of crystal are produced in equimolar amounts, each containing a single enantiomer.

[0071] The compound of formula (I) can show tautomerism and structural isomerism.For example, the compound of formula (I) can exist in several tautomeric forms, including enol and imine forms, and ketone and enamine forms, and geometric isomers and mixtures thereof.All these tautomeric forms are included in the scope of the compound of formula (I).Tautomers are present in the solution as a mixture of tautomers.In solid form, usually one tautomer is dominant.Even if a tautomer can be described, the present invention also includes all tautomers of the compound of formula (I).

[0072] The present invention also includes isotopically labeled compounds, which are the same as those described for the compounds of formula (I), but in which one or more atoms are replaced by atoms having an atomic mass or mass number different from that found in nature. Isotopes that may be incorporated into compounds of formula I (or formula II, formula III) include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as, but not limited to: 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32P. 35 S. 18 F and 36 Certain isotope-labeled compounds of formula I (or formula II, formula III), for example, compounds wherein a radioactive isotope (such as 3 H and 14 C), due to their ease of preparation and detectability, are useful in drug and / or substrate tissue distribution assays. Heavier isotopes such as 2 H, due to its greater metabolic stability, for example, prolonged half-life in vivo or reduced dosage requirements, can provide certain therapeutic advantages. Isotopically labeled compounds of Formula I (or Formula II, Formula III) can generally be prepared by replacing a non-isotopically labeled reagent with an isotopically labeled reagent.

[0073] The compounds of the present application can be used in the form of salts derived from inorganic or organic acids. Certain compounds have advantages such as enhanced drug stability under different temperatures and humidity conditions, or desired solubility in water / oil, due to the physical properties of one or more salts. In some cases, the salts of the compounds can also be used as auxiliary agents for the separation, purification and / or analysis of the compounds.

[0074] On the other hand, the present application also provides a crystalline form A of the compound of formula (I),

[0075] In the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 8.2±0.2° and 11.3±0.2°.

[0076] In certain embodiments, in the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed as a diffraction angle 2θ, the crystalline form A may further show a characteristic peak at at least one of 6.8±0.2°, 15.7±0.2°, 17.0±0.2°, 17.6±0.2°, 19.6±0.2°, 20.6±0.2°, 21.2±0.2°, 23.9±0.2° and 24.7±0.2° 2θ angles.

[0077] For example, in an X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of a diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 6.8±0.2°, 8.2±0.2°, and 11.3±0.2°.

[0078] For example, in an X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of a diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 8.2±0.2°, 11.3±0.2°, and 15.7±0.2°.

[0079] For example, in an X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of a diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 8.2±0.2°, 11.3±0.2°, and 17.0±0.2°.

[0080] For example, in an X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of a diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 8.2±0.2°, 11.3±0.2°, and 17.6±0.2°.

[0081] For example, in an X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of a diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 8.2±0.2°, 11.3±0.2°, and 19.6±0.2°.

[0082] For example, in an X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of a diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 8.2±0.2°, 11.3±0.2°, and 20.6±0.2°.

[0083] For example, in an X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of a diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 8.2±0.2°, 11.3±0.2°, and 21.2±0.2°.

[0084] For example, in an X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of a diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 8.2±0.2°, 11.3±0.2°, and 23.9±0.2°.

[0085] For example, in an X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of a diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 8.2±0.2°, 11.3±0.2°, and 24.7±0.2°.

[0086] For example, in the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 6.8±0.2°, 8.2±0.2°, 11.3±0.2°, 15.7±0.2°, and 17.6±0.2°.

[0087] For example, in the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 6.8±0.2°, 8.2±0.2°, 11.3±0.2°, 15.7±0.2°, 17.0±0.2°, and 17.6±0.2°.

[0088] For example, in the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 6.8±0.2°, 8.2±0.2°, 11.3±0.2°, 15.7±0.2°, 17.0±0.2°, and 17.6±0.2°.

[0089] In certain embodiments, the crystalline form A of the compound of formula (I) may exhibit an endothermic peak at about 120.7±1° C. in a differential scanning calorimetry test. For example, the crystalline form A of the compound of formula (I) may exhibit an endothermic peak at about 120.73° C. in a differential scanning calorimetry test.

[0090] For example, in the X-ray powder diffraction pattern of the crystalline form A of the compound of formula (I) obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 8.2±0.2° and 11.3±0.2°, and the crystalline form A of the compound of formula (I) shows an endothermic peak at approximately 120.7±1°C in a differential scanning calorimetry test.

[0091] In certain embodiments, the X-ray powder diffraction pattern of Form A of the compound of formula (I) may be substantially the same as that in FIG1 .

[0092] In certain embodiments, the DSC spectrum of Form A of the compound of formula (I) may be substantially the same as that shown in FIG. 2 .

[0093] On the other hand, the present application also provides a crystalline form B of the compound of formula (I),

[0094] In the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form B shows characteristic peaks at 2θ angles of 7.0±0.2°, 7.8±0.2° and 21.1±0.2°.

[0095] In certain embodiments, in the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed as a diffraction angle 2θ, the crystalline form B may further show a characteristic peak at at least one of 14.0±0.2°, 11.2±0.2°, 19.6±0.2°, 17.5±0.2°, 28.2±0.2°, 20.5±0.2°, 26.2±0.2°, 20.9±0.2° and 19.8±0.2° 2θ angles.

[0096] For example, in the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form B shows characteristic peaks at 7.0±0.2°, 7.8±0.2°, 21.1±0.2° and 14.0±0.2° 2θ.

[0097] For example, in the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form B shows characteristic peaks at 2θ angles of 7.0±0.2°, 7.8±0.2°, 21.1±0.2° and 11.2±0.2°.

[0098] For example, in the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form B shows characteristic peaks at 2θ angles of 7.0±0.2°, 7.8±0.2°, 21.1±0.2° and 19.6±0.2°.

[0099] For example, in the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form B shows characteristic peaks at 2θ angles of 7.0±0.2°, 7.8±0.2°, 21.1±0.2° and 17.5±0.2°.

[0100] For example, in the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form B shows characteristic peaks at 2θ angles of 7.0±0.2°, 7.8±0.2°, 21.1±0.2° and 28.2±0.2°.

[0101] For example, in the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form B shows characteristic peaks at 2θ angles of 7.0±0.2°, 7.8±0.2°, 21.1±0.2° and 20.5±0.2°.

[0102] For example, in the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form B shows characteristic peaks at 2θ angles of 7.0±0.2°, 7.8±0.2°, 21.1±0.2° and 26.2±0.2°.

[0103] For example, in the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form B shows characteristic peaks at 2θ angles of 7.0±0.2°, 7.8±0.2°, 21.1±0.2° and 20.9±0.2°.

[0104] For example, in the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form B shows characteristic peaks at 2θ angles of 7.0±0.2°, 7.8±0.2°, 21.1±0.2° and 19.8±0.2°.

[0105] For example, in the X-ray powder diffraction pattern obtained using Cu-Kα radiation and expressed in terms of diffraction angle 2θ, the crystalline form B shows characteristic peaks at 2θ angles of 7.0±0.2°, 7.8±0.2°, 21.1±0.2°, 14.0±0.2°, 11.2±0.2°, 19.6±0.2°, 17.5±0.2°, 28.2±0.2°, 20.5±0.2°, 26.2±0.2°, 20.9±0.2° and 19.8±0.2°.

[0106] In certain embodiments, the crystalline Form B of the compound of formula (I) may exhibit endothermic peaks at 95.1±1° C. and 113.4±1° C. in a differential scanning calorimetry test. For example, the crystalline Form B of the compound of formula (I) may exhibit endothermic peaks at approximately 95.08° C. and approximately 113.37° C. in a differential scanning calorimetry test.

[0107] For example, in the X-ray powder diffraction pattern of the compound of formula (I) obtained using Cu-Kα radiation and expressed as a diffraction angle 2θ, the crystalline form B shows characteristic peaks at 2θ angles of 7.0±0.2°, 7.8±0.2° and 21.1±0.2°, and the crystalline form B of the compound of formula (I) shows endothermic peaks at 95.1±1°C and 113.4±1°C in the differential scanning calorimetry test.

[0108] In certain embodiments, the X-ray powder diffraction pattern of Form B of the compound of formula (I) may be substantially the same as that shown in FIG3 .

[0109] In certain embodiments, the DSC spectrum of Form B of the compound of formula (I) may be substantially the same as that shown in FIG4 .

[0110] In the present application, the compound of formula (I) can be a JAK inhibitor prodrug. For example, the JAK inhibitor can be tofacitinib

[0111] On the other hand, the present application also provides a pharmaceutical composition comprising the compound of formula (I) described herein, the crystalline form A of the compound of formula (I), the crystalline form B of the compound of formula (I), and optionally a pharmaceutically acceptable carrier.

[0112] On the other hand, the present application also provides a drug combination or kit comprising: 1) an anti-tumor agent; and 2) the compound of formula (I), the crystalline form A of the compound of formula (I), the crystalline form B of the compound of formula (I) or the pharmaceutical composition.

[0113] On the other hand, the present application also provides a drug combination or kit comprising: 1) an EGFR inhibitor; and 2) the compound of formula (I), the crystalline form A of the compound of formula (I), the crystalline form B of the compound of formula (I) or the pharmaceutical composition.

[0114] In the present application, the pharmaceutical combination or kit may further include a buffer.

[0115] In the present application, the pharmaceutical combination or kit may further include an excipient.

[0116] In the present application, the component 1) and the component 2) in the pharmaceutical combination or kit may not be mixed with each other.

[0117] In the present application, the component 2) in the pharmaceutical combination kit does not substantially affect the therapeutic effect of the component 1).

[0118] In the present application, the term "substantially does not affect" may mean that the therapeutic effect of the compound or pharmaceutically acceptable salt thereof in 2) of the pharmaceutical combination or kit and the anti-tumor agent / EGFR inhibitor in 1) is equivalent to, or does not produce a significant disadvantage compared to, the therapeutic effect of the anti-tumor agent / EGFR inhibitor used alone. For example, for any subject, the degree of reduction in tumor volume caused by the compound of formula (I) or pharmaceutically acceptable salt thereof in 2) of the pharmaceutical combination or kit and the anti-tumor agent / EGFR inhibitor in 1) is the same as that of the anti-tumor agent / EGFR inhibitor used alone, or the degree of reduction is not less than about 5%, not less than about 4%, not less than about 3%, not less than about 2%, not less than about 1%, not less than about 0.5%, not less than about 0.1%, not less than about 0.01%, not less than about 0.001%, or less.

[0119] Methods and uses

[0120] On the other hand, the present application also provides the use of the compound of formula (I), the crystalline form A of the compound of formula (I), the crystalline form B of the compound of formula (I), or the pharmaceutical composition as a prodrug of a JAK inhibitor. For example, the JAK inhibitor can be tofacitinib.

[0121] On the other hand, the present application also provides the compound of formula (I), the crystalline form A of the compound of formula (I), the crystalline form B of the compound of formula (I), or the use of the pharmaceutical composition in the preparation of a drug, which is used to prevent and / or treat diseases and / or conditions.

[0122] On the other hand, the present application also provides a method for preventing and / or treating diseases and / or conditions, which comprises administering the compound of formula (I), the crystalline form A of the compound of formula (I), the crystalline form B of the compound of formula (I), or the pharmaceutical composition to a subject in need.

[0123] As used herein, the term "prevention" generally refers to preventing the onset, recurrence, or spread of a disease or one or more of its symptoms. "Prevention" is used interchangeably with "prophylactic treatment" in this application. In certain embodiments, "prevention" generally refers to providing a patient with a disease or condition described herein with a drug described herein, with or without other drugs described herein, prior to the onset of symptoms.

[0124] The term "treat" as used herein generally refers to eliminating or ameliorating a disease, or one or more symptoms associated with a disease. In some embodiments, treatment generally refers to eliminating or ameliorating a disease by administering one or more therapeutic agents to a patient suffering from the disease. In some embodiments, "treatment" can be the administration of a drug after the onset of symptoms of a particular disease, with or without the presence of other therapeutic agents.

[0125] The term "subject" used in this application generally refers to humans or non-human animals (including mammals) in need of diagnosis, prognosis, improvement, prevention and / or treatment of diseases, particularly those subjects in need of treatment or prevention with JAK inhibitors.

[0126] In some embodiments, the subject can be a human or a non-human mammal. Non-human mammals can include any mammalian species other than humans, such as livestock animals (e.g., cattle, pigs, sheep, chickens, rabbits, or horses), or rodents (e.g., rats and mice), or primates (e.g., gorillas and monkeys), or domestic animals (e.g., dogs and cats).

[0127] Diseases or conditions associated with anti-tumor agents

[0128] In the present application, the diseases and / or conditions may include diseases and / or conditions caused by administration of anti-tumor agents.

[0129] In some embodiments, the subject may include a cancer patient.

[0130] For example, the cancer patient may have been, is currently, and / or will be administered an anti-tumor agent.

[0131] In some embodiments, after the compound of the present application is applied, the severity of the disease or illness associated with the anti-tumor agent of the subject is alleviated. In some embodiments, after the compound of the present application is applied, the severity of the rash caused by the EGFR dysfunction of the subject is alleviated. In some embodiments, the alleviation can be judged according to the grading standards of NCI-CTCAE V5.0, for example, the severity of the epithelial tissue disease of the subject is reduced from 5 grades to 1 grade (for example, 5 grades are reduced to 4 grades, 5 grades are reduced to 3 grades, 5 grades are reduced to 2 grades, 4 grades are reduced to 3 grades, 4 grades are reduced to 2 grades, 4 grades are reduced to 1 grade, 3 grades are reduced to 2 grades, 3 grades are reduced to 1 grade or 2 grades are reduced to 1 grade). In some embodiments, the alleviation can generally refer to that the onset or development of the rash caused by the EGFR dysfunction of the subject is postponed.

[0132] In some embodiments, administration of an effective amount of a compound described herein to a subject in need thereof can reduce the severity of the subject's rash from Grade 5 to Grade 1 (e.g., Grade 5 to Grade 4, Grade 5 to Grade 3, Grade 5 to Grade 2, Grade 4 to Grade 3, Grade 4 to Grade 2, Grade 4 to Grade 1, Grade 3 to Grade 2, Grade 3 to Grade 1, or Grade 2 to Grade 1).

[0133] In the present application, the diseases and / or conditions may include skin diseases and / or conditions.

[0134] In the present application, the disease or condition associated with an anti-tumor agent includes a side effect associated with an anti-tumor agent. For example, the disease or condition associated with an anti-tumor agent may refer to a disease or condition caused by the administration of one or more anti-tumor agents, or the disease or condition is caused or aggravated after the administration of the anti-tumor agent.

[0135] In the absence of prophylaxis or treatment, the disease or condition may appear or worsen after about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 1 day, about 2 days, about 4 days, about 7 days, about 2 weeks, about 3 weeks, about 1 month, about 2 months, or more after the administration of the anti-tumor agent.

[0136] For example, the anti-neoplastic agent-associated diseases or disorders may include anti-neoplastic agent-associated alopecia, anti-neoplastic agent-associated body odor, anti-neoplastic agent-associated bullous dermatitis, anti-neoplastic agent-associated dry skin, anti-neoplastic agent-associated eczema, anti-neoplastic agent-associated erythema multiforme, anti-neoplastic agent-associated erythroderma, anti-neoplastic agent-associated lipoatrophy, anti-neoplastic agent-associated hair color change, anti-neoplastic agent-associated abnormal hair texture, anti-neoplastic agent-associated hirsutism, anti-neoplastic agent-associated hyperhidrosis, anti-neoplastic agent-associated hyperkeratosis, anti-neoplastic agent-associated hypertrophy ... chosis, hypohidrosis associated with antineoplastic agents, lipomegaly associated with antineoplastic agents, nail changes associated with antineoplastic agents, nail discoloration associated with antineoplastic agents, nail loss associated with antineoplastic agents, nail elevation associated with antineoplastic agents, skin pain associated with antineoplastic agents, hand-foot syndrome associated with antineoplastic agents, photosensitivity associated with antineoplastic agents, pruritus associated with antineoplastic agents, purpura associated with antineoplastic agents, acneiform rash associated with antineoplastic agents, maculopapular rash associated with antineoplastic agents, scalp pain associated with antineoplastic agents, skin atrophy associated with antineoplastic agents, skin hyperpigmentation associated with antineoplastic agents skin hyperpigmentation, skin hypopigmentation associated with antineoplastic agents, skin induration associated with antineoplastic agents, skin ulcers associated with antineoplastic agents, Stevens-Johnson syndrome associated with antineoplastic agents, subcutaneous emphysema associated with antineoplastic agents, telangiectasia associated with antineoplastic agents, toxic epidermal necrolysis associated with antineoplastic agents, rash and / or urticaria associated with antineoplastic agents.

[0137] For example, the disease or condition associated with the anti-tumor agent may include a disease or condition associated with EGFR abnormality. For example, the disease or condition associated with EGFR abnormality may include a rash associated with EGFR abnormality.

[0138] In the present application, the anti-tumor agent may include a small molecule compound, a small molecule conjugate, a protein (eg, an antibody) and / or a polynucleotide (eg, DNA or RNA).

[0139] For example, the anti-tumor agent may be a targeted therapeutic agent.

[0140] For example, the targeted therapeutic agent may include a small molecule compound. For example, the targeted therapeutic agent may include an antibody or an antigen-binding fragment thereof. For example, the antibody may include a monoclonal antibody, a multispecific antibody, a chimeric antibody, a humanized antibody, a fully human antibody and / or an antibody drug conjugate. For example, the antigen-binding fragment may include Fab, Fab', F(ab )2 , Fv fragment, F(ab')2, scFv, di-scFv and / or dAb. For example, the targeted therapeutic agent can target molecules inside tumor cells, on the cell surface and / or in the tumor microenvironment. For example, the targeted therapeutic agent can target proteins and / or nucleic acid molecules of tumor cells. For example, the targeted therapeutic agent can target tumor antigens. For example, the targeted therapeutic agent can target EGFR, ALK, MEK, VEGFR, FGFR, PDGFR, ABL, BTK, KIT, AKT, TORC, HER2, HER3, HER4, PI3K, CDK, JAK, ROS1, RET, MET, KRAS, BRAF, BCRP, NTRK, RAS, MSI, PR / ER, BCR / ABL, HDAC, FAK, PYK2, CD20, PD-L1 and / or BRCA1 / 2, or mutants thereof.

[0141] For example, the targeted therapeutics may include hormone therapies, signal transduction inhibitors, gene expression regulators, apoptosis inducers, angiogenesis inhibitors, and / or toxin delivery molecules.

[0142] For example, the targeted therapeutic agent can be a tyrosine kinase inhibitor. For example, the targeted therapeutic agent can be an EGFR inhibitor, a MEK inhibitor, an ALK inhibitor, a BTK inhibitor, a PI3K inhibitor, an AKT inhibitor, a VEGFR inhibitor, an mTOR inhibitor, an HDAC inhibitor, a KIT inhibitor, an FGFR inhibitor, a FAK inhibitor, a BCRP inhibitor, an EGFR / cMET inhibitor and / or an SRC inhibitor, and combinations thereof.

[0143] For example, the targeted therapeutic agent can be an EGFR inhibitor. For example, the EGFR inhibitor includes a small molecule EGFR inhibitor, a protein macromolecule that specifically binds to EGFR, RNAi that inhibits EGFR protein expression, and / or an antisense oligonucleotide that inhibits EGFR protein expression. For example, the small molecule EGFR inhibitor includes a small molecule EGFR inhibitor that reversibly binds to EGFR, a small molecule EGFR inhibitor that irreversibly binds to EGFR, and / or a small molecule EGFR inhibitor that specifically binds to mutant EGFR. For example, the EGFR inhibitors include cetuximab, gefitinib, erlotinib, icotinib, sapitinib, afatinib, lapatinib, vandetinib, neratinib, brigatinib, panitumumab, necitozumab, nimotuzumab, tesevatinib, alitinib, silitinib, rociletinib, canertinib, AZD3759, YZJ-0318, naprotinib, naquotinib, PF-06747775, SPH1188-11, P- Oziotinib, Epitinib, Varlitinib, Afatinib, HM61713, CK-101, Pyrotinib, Lelotinib, HS-10296, AP32788, Cimotinib, GMA204, Virlitinib, Yinlitinib, Nazartinib, Nocetinib, Omotinib, Osimertinib, Dacomitinib, Avitinib, EAI045, Lazertinib, Alflutinib, Mobocertinib, Savolitinib, Almonertinib, Trastuzumab, Tepotinib, Irbinitinib, Cemiplimab, Pyrotinib, Dacomitinib, Neratinib, Olmutinib, Mereletinib, Bosutini b. Icotinib, Vandetanib, Lapatinib, Befotertinib, Poziotinib, Larotinib, BPI-7711, SKLB-1028, Famitinib, Dovitinib and / or Zorifertinib.

[0144] For example, the targeted therapeutic agent can be a VEGFR inhibitor. For example, the VEGFR inhibitor is selected from the group consisting of Sulfatinib, Anlotinib hydrochloride, Tivozanib, Lenvatinib, Apatinib, Intedanib, Ponatinib, Axitinib, Vandetanib, Pazopanib hydrochloride and / or Sorafenib.

[0145] For example, the targeted therapeutic agent may be a FGFR inhibitor.

[0146] For example, the targeted therapeutic agent can be an ALK inhibitor.

[0147] For example, the targeted therapeutic agent may be an mTOR inhibitor. For example, the targeted therapeutic agent may be an mTORC inhibitor. For example, the targeted therapeutic agent may be an mTORC1 inhibitor. For example, the targeted therapeutic agent may be an mTORC2 inhibitor. For example, the mTOR inhibitor is selected from the group consisting of zotarolimus, sirolimus, everolimus, and / or temsirolimus.

[0148] For example, the targeted therapeutic agent can be a BTK inhibitor. For example, the BTK inhibitor is selected from the group consisting of Orelabrutinib, Tirabrutinib hydrochloride, Zanubrutinib, Acalabrutinib, Ibrutinib, Dasatinib, Pirtobrutinib, Tolebrutinib, Rilzabrutinib, Fenebrutinib and / or Evobrutinib.

[0149] For example, the targeted therapeutic agent can be a MEK inhibitor. For example, the MEK inhibitor can be selected from the group consisting of Selumetinib sulfate, Binimetinib, Cobimetinib, Trametinib and / or GSK-1120212.

[0150] For example, the targeted therapeutic agent can be a PI3K inhibitor. For example, the PI3K inhibitor can be selected from the group consisting of Umbralisib, Alpelisib, Duvelisib, Copanlisib hydrochloride, Idelalisib, Zandelisib, Buparlisib, Enzastaurin hydrochloride, Paxalisib, Leniolisib, Rigosertib, Dactolisib, Nortriptyline and / or Parsaclisib.

[0151] For example, the targeted therapeutic agent can be an AKT inhibitor. For example, the AKT inhibitor can be Ipatasertib.

[0152] For example, the targeted therapeutic agent may be an EGFR / cMET inhibitor.

[0153] For example, the targeted therapeutic agent can be a BRAF inhibitor. For example, the BRAF inhibitor can be selected from the group consisting of Tepotinib, Dabrafenib, Vemurafenib and / or encorafenib.

[0154] For example, the targeted therapeutic agent may include a BRAF inhibitor and a MEK inhibitor. For example, the targeted therapeutic agent may include Dabrafenib and Trametinib.

[0155] For example, the therapeutic agent targeting CD20 may be Rituximab.

[0156] For example, the targeted therapeutic agent may include an EGFR inhibitor.For example, the targeted therapeutic agent may not include an EGFR inhibitor.

[0157] For example, the anti-tumor agent can be an immunotherapeutic agent. For example, the immunotherapeutic agent can alter an immune response in a subject. For example, the immunotherapeutic agent can enhance an immune response in a subject. For example, the immunotherapeutic agent can be an immune checkpoint inhibitor, a modified immune cell, and / or a vaccine. For example, the immunotherapeutic agent can be an antibody. For example, the immunotherapeutic agent can be a PD-1 inhibitor, a PD-L1 inhibitor, and / or a CTLA-4 inhibitor.

[0158] For example, the anti-tumor agent may be selected from the group consisting of afatinib, dacomitinib, osimertinib, EAI045, gefitinib, almonertinib, pyrotinib, brigatinib, neratinib, olmutinib, bosutinib, icotinib, vandetanib, lapatinib, alflutinib, BPI-7711, mobocertinib, dovitinib, zorifertinib, varlitinib, orelabrutinib, tirabrutinib, zanubrutinib, acalabrutinib, ibrutinib, dasatinib, pirtobrutinib, tolebrutinib, rilzabrutinib, fenebrutinib, evobrutinib, selumetinib, binimetinib, cobimetinib, trametinib, regorafenib, GSK-1120212, alpelisib, duvelisib, copanlisib, idelalisib, nortriptyline, i navolisib, dactolisib, apitolisib, parsaclisib, buparlisib, rigosertib, enzastaurin, paxalisib, leniolisib, ipatasertib, zotarolimus, sirolimus, everolimus, temsirolimus, sorafenib, apatinib, lenvatinib, sunitinib, cabozantinib, axitinib, nintedanib, brivanib, vatalanib, fruquintinib, dabrafenib, vemurafenib, encorafenib, pazopanib, crizotinib, panobinostat, erlotinib, rituximab, panitumumab, cetuximab, Ticilimumab, Erfonrilimab, BA-3071, MEDI-5752, defactinib, Zalifrelimab, Cadonilimab, BCD-217, ipilimumab, Tremelimumab, Quavonlimab,atezolizumab, durvalumab, Camrelizumab, Tislelizumab, Sintilimab, Toripalimab, pembrolizumab, nivolumab, Amivantamab, MCLA-129, EMB-01, LY3164530, Roche Glycart anti-EGFR / cMet, Genentech Anti-met / EGFR, Samsung Anti-EGFR / cMet, Merck serono Anti-cmet / egfr, and GB263, and combinations thereof.

[0159] In the present application, the disease or condition associated with the anti-tumor agent may include a disease or condition associated with the combined use of two or more anti-tumor agents. In the present application, the disease or condition may include a disease or condition associated with the combined use of the anti-tumor agent with one or more other therapies. In the present application, the disease or condition may include a disease or condition associated with EGFR abnormalities. In the present application, the disease or condition may include a rash associated with EGFR abnormalities.

[0160] Rash associated with EGFR dysfunction

[0161] In the present application, the disease or disorder may include a rash associated with EGFR dysfunction. In the present application, the term "EGFR" generally refers to epidermal growth factor receptor (EGFR), also known as ErbB1 or HER1, a 170kDa transmembrane glycoprotein encoded by the c-erbB1 proto-oncogene. EGFR is a member of the human epidermal growth factor receptor (HER) family of receptor tyrosine kinases (RTKs), which also includes HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4). EGFR signaling is initiated by ligand binding, followed by induction of conformational changes, homodimerization or heterodimerization of the receptor with other ErbB family members, and trans autophosphorylation of the receptor, etc. (see, Ferguson et al., Annu Rev Biophys, 37: 353-73, 2008), to initiate a signal transduction cascade, thereby ultimately affecting a variety of cellular functions (e.g., cell proliferation and survival). Increased expression of EGFR or its kinase activity is associated with a range of human cancers (see, Mendelsohn et al., Oncogene 19:6550-6565, 2000; GrUnwald et al., J Natl Cancer Inst 95:851-67, 2003; Mendelsohn et al., Semin Oncol 33:369-85, 2006). Increased expression of EGFR is known to be found in numerous cancers, such as brain glioma, breast cancer, ovarian cancer, and cervical cancer.

[0162] In some cases, the rash associated with the EGFR dysfunction includes a rash associated with EGFR being suppressed. In this application, the term "EGFR is suppressed" includes a reduction in EGFR activity, expression or quantity caused by any reason (for example, caused by treatment or caused by the subject's own physical condition). In some embodiments, EGFR is suppressed and generally refers to a reduction in the activity or quantity of EGFR by at least 10%. In some embodiments, EGFR is suppressed and generally refers to a reduction in the activity or quantity of EGFR by at least 20%, 40%, 50%, 80%, 90%, 95% or more. In some embodiments, the reduction is compared with the standard value in the same subject (for example, the same normal person or the same type of patient). In some embodiments, the reduction is compared with the numerical value of the same subject some time ago.

[0163] In some cases, EGFR is inhibited due to the use of EGFR inhibitors. In this application, the term "EGFR inhibitor" generally refers to any EGFR inhibitor known in the art or discovered in the future, including any substance that, when administered to a subject, results in the inhibition of biological activity associated with EGFR activity in the subject (including the inhibition of downstream biological effects produced by any EGFR binding to its natural ligand). In some embodiments, EGFR inhibitors include any reagent that can block EGFR activity or any downstream biological effects thereof during the treatment of cancer.

[0164] EGFR inhibitors can be determined or screened by methods well known in the art, for example, by detecting changes in EGFR expression levels after administration of a test compound. Detection of EGFR expression levels can be performed by methods well known in the art, for example, immunohistochemistry, PCR, RT-PCR, in situ hybridization, Southern blot, Western blot, Northern blot, spectrophotometry, and ELISA.

[0165] For example, the EGFR inhibitor can be used to treat cancer in the subject.In this application, the term "cancer" generally refers to any medical condition mediated by tumor or malignant cell growth, proliferation or metastasis, and causing solid tumors and non-solid tumors (e.g., leukemia).

[0166] For example, EGFR inhibitors can block the kinase activity of EGFR receptor by directly binding to its intracellular domain; or occupy the ligand binding site or a portion of the EGFR receptor, thereby making the EGFR receptor inaccessible to its natural ligand and causing its biological activity to be reduced or blocked; or increase the ubiquitination and endocytic degradation of EGFR by regulating the dimerization of EGFR polypeptide or regulating the interaction of EGFR polypeptide with other proteins, thereby reducing EGFR activity.

[0167] For example, the EGFR inhibitor may be a non-specific inhibitor of EGFR, ie, the inhibitor may inhibit other target proteins in addition to EGFR.

[0168] For example, EGFR inhibitors act directly on EGFR protein or nucleic acid encoding EGFR protein. In some embodiments, EGFR inhibitors act directly on EGFR protein. When the term "directly act on" is used in this application to describe an inhibitor and a target protein, it generally refers to the direct binding (including covalent and non-covalent binding) between the inhibitor and the target protein without the need for other molecules.

[0169] For example, the EGFR inhibitor can be a small molecule EGFR inhibitor, a protein macromolecule that specifically binds EGFR (e.g., an antibody or its antigen binding fragment) or RNAi or antisense oligonucleotides that suppress EGFR protein expression. For example, the EGFR inhibitor can be a small molecule EGFR inhibitor or a protein macromolecule that specifically binds EGFR (e.g., an antibody or its antigen binding fragment).

[0170] In this application, the term "nucleic acid" generally refers to a polynucleotide molecule composed of monomeric nucleotides. Nucleic acids include ribonucleic acid (RNA), deoxyribonucleic acid (DNA), single-stranded nucleic acid (ssDNA), double-stranded nucleic acid (dsDNA), small interfering ribonucleic acid (siRNA) and microRNA (miRNA). Other non-limiting examples of polynucleotides include genes, gene fragments, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, shRNA, single-stranded short or long RNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, control regions, isolated RNA of any sequence, nucleic acid probes and primers. Nucleic acids can be linear or circular.

[0171] In this application, the term "RNAi" generally refers to RNA interference technology, which is a process in which exogenous or endogenous double-stranded RNA molecules or small RNA molecules inhibit gene expression or translation by targeting mRNA and specifically degrading it.

[0172] As used herein, the term "oligonucleotide" generally refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), or any mimics or structurally modified nucleic acids thereof. The term includes oligonucleotides composed of naturally occurring nucleobases, sugars, and covalent internucleoside (backbone) linkages, as well as non-naturally occurring oligonucleotides having similar functions.

[0173] In this application, the term "antisense oligonucleotide" generally refers to a single-stranded oligonucleotide having a nucleobase sequence that allows at least partial hybridization to a corresponding region or fragment of a target nucleic acid.

[0174] In this application, the term "small molecule EGFR inhibitor" may include small molecule EGFR inhibitors that reversibly bind to EGFR (e.g., gefitinib, erlotinib, sapitinib and icotinib), small molecule EGFR inhibitors that irreversibly bind to EGFR (e.g., afatinib, dacomitinib, lapatinib, etc.), and small molecule EGFR inhibitors that irreversibly bind to EGFR (e.g., afatinib, dacomitinib, lapatinib, etc.). GW572016 GlaxoSmithKline), vandetinib (e.g., ZACTIMA™, ZD6474), lenvatinib, canertinib, valitinib, and neratinib) and / or small molecule EGFR inhibitors that specifically bind to mutant EGFR (e.g., osimertinib, nazartinib, nocetinib, omotinib, avitinib, and EAI045).

[0175] The protein macromolecule that specifically binds to EGFR can be an antibody, antibody variant, fusion protein, derivative or fragment thereof to EGFR. In some embodiments, the protein macromolecule that specifically binds to EGFR is an antibody or antigen-binding fragment thereof that specifically binds to EGFR.

[0176] As used herein, the term "specifically binds" when used to describe an EGFR inhibitor generally means that the EGFR inhibitor can recognize EGFR in a complex mixture, and the binding constant of the inhibitor to EGFR is at least twice that of its binding constant to other non-specific binding proteins.

[0177] In some cases, the EGFR inhibitor can be used in combination with one or more other cancer treatments. The other cancer treatments can be conventional methods for treating cancer in this area, such as cytotoxic anticancer agents, immunotherapy anticancer agents or hormone therapy anticancer agents. According to the application, the medicine for cancer treatment can also be used in combination with radiotherapy or surgery. In some embodiments, when the EGFR inhibitor and other anticancer agents are used in combination, they can be applied to the subject simultaneously, or separately applied at certain intervals.

[0178] In the present application, the rash associated with EGFR dysfunction can be a rash associated with EGFR inhibition. In the present application, the rash associated with EGFR dysfunction can be a rash associated with EGFR inhibitors. In the present application, the rash associated with EGFR dysfunction can be a rash that occurs after administering an EGFR inhibitor.

[0179] In the present application, the rash associated with EGFR dysfunction may include acne vulgaris associated with EGFR dysfunction, papulopustular rash associated with EGFR dysfunction, acne rosacea associated with EGFR dysfunction, pruritus rash associated with EGFR dysfunction, acneiform rash associated with EGFR dysfunction, cellulitis associated with EGFR dysfunction, Lyme disease associated with EGFR dysfunction, allergic reaction associated with EGFR dysfunction, hidradenitis suppurativa associated with EGFR dysfunction, hives associated with EGFR dysfunction, dermatitis associated with EGFR dysfunction, cradle cap associated with EGFR dysfunction, purpura associated with EGFR dysfunction, pityriasis rosea associated with EGFR dysfunction, rosea), erythema associated with EGFR dysfunction, shingles associated with EGFR dysfunction, bruises associated with EGFR dysfunction and / or xanthelasmas associated with EGFR dysfunction, melanoma associated with EGFR dysfunction, basal cell carcinoma associated with EGFR dysfunction, squamous cell carcinoma associated with EGFR dysfunction, Kaposi's sarcoma associated with EGFR dysfunction, erythema annulare centrifugum associated with EGFR dysfunction, folliculitis associated with EGFR dysfunction, follicular papules associated with EGFR dysfunction, xerosis associated with EGFR dysfunction, eczema xerotica associated with EGFR dysfunction and / or papillary pustulosis associated with EGFR dysfunction.

[0180] Skin diseases and / or conditions

[0181] In the present application, the diseases and / or conditions may include skin diseases or conditions. For example, the patient to whom the compounds described herein are administered may be a patient suffering from a skin disease. The skin diseases or conditions in the present application generally refer to diseases or conditions occurring in the skin and skin appendages. In the present application, the skin diseases or conditions may be caused by various reasons. For example, the skin diseases or conditions may be caused by an anti-tumor agent or may not be caused by an anti-tumor agent. For example, the skin diseases or conditions may be caused by an infection; for example, the skin diseases or conditions may be caused by the side effects of different drugs; for example, the skin diseases or conditions may be caused by an abnormal immune system; for example, the skin diseases or conditions may be caused by nerve damage; or, the skin diseases or conditions may also be caused by other factors. For example, the skin diseases or conditions include immune skin diseases. For example, the skin diseases or conditions include atopic dermatitis, alopecia areata, or psoriasis. For example, the skin diseases or conditions may include subcutaneous tissue diseases or conditions. For example, the skin disease or condition can include alopecia, body odor, bullous dermatitis, dry skin, eczema, erythema multiforme, erythroderma, lipoatrophy, hair color change, abnormal hair texture, hirsutism, hyperhidrosis, hyperkeratosis, hypertrichosis, hypohidrosis, lipohypertrophy, nail changes, nail discoloration, nail loss, nail elevation, skin pain, hand-foot syndrome, photosensitivity, pruritus, purpura, acneiform rash, maculopapular rash, scalp pain, skin atrophy, skin hyperpigmentation, skin hypopigmentation, skin induration, skin ulcer, Stevens-Johnson syndrome, subcutaneous emphysema, telangiectasia, toxic epidermal necrolysis, rash, and / or urticaria.

[0182] For example, the skin disease or disorder may be a rash.

[0183] As used herein, the term "rash" generally refers to changes in the skin that affect the color, appearance, or texture of the skin. A rash can be localized to just one part of the body or affect the entire skin. A rash can also include hives. The rash can be an immune rash and / or a non-immune rash.

[0184] For example, the pathological manifestations of the rash may include obvious changes in skin epidermal growth and / or differentiation, changes in terminal differentiation of keratinocytes, dense corneal plasticity and epidermal parakeratosis, damage to sebaceous glands and / or hair follicle infundibulum, with or without signs of infection, damaged epidermal barrier, epidermal corneal fissures, cytokine production, inflammatory cell infiltration (such as neutrophils, lymphocytes), bacterial infection, capillary dilation, pigmentation and / or dense epithelial inflammatory permeability.

[0185] For example, the clinical manifestations of the rash may be erythema, dry skin, itching, scaly patches, tenderness, burning sensation, cracks, pustules, follicles, ulcers, abscesses, red raised bumps and / or purulent lesions.

[0186] For example, the site of occurrence of the rash can be the epidermis, for example, including the seborrheic areas of the skin. For example, the site of occurrence of the rash can include the scalp, face, neck, chest, upper back, limbs, lower back, abdomen, buttocks, periodontal area, abdomen, palms, soles, nails and / or mucous membranes.

[0187] In the present application, the rash may include acne vulgaris, papulopustular rash, acne rosacea, boil, acneiform rash, cellulitis, Lyme disease, allergic reaction, hidradenitis suppurativa, hives, dermatitis, cradle cap, purpura, pityriasis rosea, erythema, shingles, bruises and / or xanthelasma, melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, erythema annulare centrifugum), folliculitis, follicular papules, xerosis, eczema xerotica, and / or nipple pustulosis.

[0188] Without intending to be bound by any theory, the following embodiments are merely intended to illustrate various technical solutions of the present invention and are not intended to limit the scope of the present invention.

[0189] Example

[0190] Preparation of the compound of Example 1

[0191] Compound 2: Preparation of 2-[tert-butoxycarbonyl(methyl)amino]ethyl cyclopropanecarboxylate

[0192] Compound 1 [tert-butyl N-(2-hydroxyethyl)-N-methyl-carbamate (50 g, 2.85 mmol, 1 eq)] and triethylamine (57.8 g, 571 mmol, 79.4 mL, 2.0 eq) were added to 500 mL of dichloromethane. Cyclopropanecarbonyl chloride (44.7 g, 428 mmol, 38.9 mL, 1.5 eq) was added dropwise under nitrogen protection, maintaining the temperature at 0-5 degrees Celsius. After the addition was complete, stirring was continued for 2 hours. The compound was consumed by TLC (Petroleum ether:Ethyl acetate=3:1, R f =0.03). The reaction mixture was quenched by adding 200 mL of water. After separation, the organic phase was washed with 200 mL of water and concentrated in vacuo to obtain a crude yellow oil (50 g). 1 H NMR(400MHz,CHLOROFORM-d)δ(ppm):4.18(br s,2H),3.46(br s,2H),2.92(br s,3H),1.57-1.64(m,1H),1.46(s,9H),0.98-1.04(m,2H),0.87(br d,J=4.0Hz,2H).

[0193] Compound 3: Preparation of (methylamino)ethyl cyclopropanecarboxylate

[0194] Compound 2 (50 g, 206 mmol, 1.0 eq) was added to a mixed solvent of 300 mL of dichloromethane and 100 mL of trifluoroacetic acid at 0°C. After stirring for 2 hours, the mixture was concentrated by rotary evaporation under reduced pressure to obtain 50 g of crude compound 3.

[0195] Preparation of compound 6: (4-nitrophenyl)4-[[(3R,4R)-1-(2-cyanoacetyl)-4-methyl-3-piperidyl]-methyl-amino]pyrrolo[2,3-d]pyrimidine-7-carboxylate

[0196] Tofacitinib (100 g, 3200 mmol, 1.0 eq) was added to a mixture of dichloromethane (1000 mL) and triethylamine (64.8 g, 640 mmol, 89.1 mL, 2.0 eq), followed by the addition of p-nitrophenol carbonate (96.8 g, 480 mmol, 1.5 eq). The reaction mixture was stirred at 20 degrees Celsius for 3 hours. LCMS analysis revealed the disappearance of the reactants, and compound 6 was generated using MSI (M+H) analysis. + ,478.3.

[0197] Preparation of Compound A

[0198] Compound 3 (36.0 g, 251 mmol, 1 eq) and compound 6 (120 g, 251 mmol, 1 eq) were added to dichloromethane (800 mL), followed by triethylamine (127 g, 1.26 mol, 175 mL, 5.0 eq). The mixture was stirred at room temperature for 10 hours. LCMS confirmed the complete consumption of compound 6. The reaction was quenched by dilution with 2 L of ethyl acetate and washed with water (2 L x 5). The organic phase was separated and dried over anhydrous sodium sulfate. The crude product was concentrated by rotary evaporation under reduced pressure and purified by silica gel column chromatography to yield the desired product, Compound A (105 g, yield). The structure was confirmed by NMR and LCMS. 1 H NMR: (400MHz, DMSO-d6) δ (ppm): 8.18-8.25 (m, 1H), 7.33 (br d, J = 3.6Hz, 1H), 6.80 (br s, 1H), 4.85 (br s,1H),4.21-4.37(m,1H),3.89-4.21(m,4H),3.40-3.86(m,5H),3.28(s,3H),2.8 4-3.13(m,3H),2.31-2.44(m,1H),1.67-1.90(m,1H),1.50-1.66(m,2H),1.02(br d,J=7.2Hz,3H),0.75-0.93(m,4H). LCMS: (M+H) + ,482.2.

[0199] Example 2 Study on the Crystalline Form of Compound A

[0200] Compound A was subjected to a crystal form study. Following the process of Example 1, polymorph screening was performed using common solvents and various crystallization methods, including slow volatilization, 4-8°C slurry, room temperature slurry, 50°C slurry, anti-solvent addition, anti-antisolvent addition, cooling crystallization, gas-liquid diffusion, gas-solid diffusion, water vapor stress, polymer induction, grinding, cyclic heating and cooling, rapid melt cooling, and slow melt cooling, to obtain two main crystal forms, Form A and Form B.

[0201] The X-ray diffraction pattern of Form A is shown in Figure 1. The positions of the characteristic peaks of Form A are shown in Table 1. The DSC spectrum of Form A is shown in Figure 2. The results show that Form A has an endothermic peak at 120.73°C.

[0202] Table 1 Characteristic peaks detected by XRPD of Form A

[0203] Approximately 20 mg of the starting sample (Compound A) was weighed and dissolved in 0.1 mL of acetonitrile to obtain a clear solution. This solution was then placed in a 20 mL vial containing 3 mL of the volatile antisolvent, methyl tert-butyl ether. The 20 mL vial was sealed with a cap and maintained at room temperature to allow sufficient time for the organic vapor to interact with the solution. After three days of vapor-liquid diffusion, no solid was obtained. After two days of evaporation at room temperature with the cap open, a crystalline solid, Form B of Compound A, was obtained.

[0204] The X-ray diffraction pattern of Form B is shown in Figure 3, its DSC spectrum is shown in Figure 4, and the positions of its characteristic peaks are shown in Table 2. The results show that Form B has endothermic peaks at 95.08°C and 113.37°C.

[0205] Table 2 XRPD characteristic peaks of Form B

[0206] Example 3 In vitro enzyme inhibitory activity of the compounds of the present application

[0207] The LanceUltra Assay method was used to test the inhibitory activity of the compounds of the present application and tofacitinib on JAK targets (JAK1, JAK2, JAK3, TYK2).

[0208] 1. Preparation of Compound Dilutions: The compounds of the present invention and tofacitinib were diluted 5-fold to a 10-well concentration gradient. Transfer 200 nL of compound to a 384-well plate. Add 200 μL of 100% DMSO to two empty wells, designated as the Max well and Min well, respectively.

[0209] 2. Kinase Reaction and Termination 1) Add kinase to kinase buffer (50 mM HEPES, pH 7.5; 10 mM MgCl2; 0.01% BSA; 0.01% Tween-20; 2 mM DTT) to form an enzyme solution. 2) Transfer 10 μL of this enzyme solution to a 384-well plate reaction well. Add kinase buffer to the negative control well and incubate at room temperature for 10 minutes. 3) Add substrate and ATP and other reagents to the kinase buffer to form a substrate solution. 4) Transfer 10 μL of the substrate solution to the 384-well plate reaction well. 5) Incubate at room temperature for 60 minutes. 6) Prepare a 2x antibody-containing stop reaction solution. Add 20 μL of the stop reaction solution to the 384-well plate and incubate at room temperature for 60 minutes.

[0210] 3. Data Reading and Analysis 1) Fluorescence readings were obtained using an Envision 2104 Multilabel Reader. 2) Percent inhibition was calculated. Curve fitting analysis was performed using XLFit to determine the IC50 value.

[0211] 4. The experimental results are shown in Table 3:

[0212] Table 3 In vitro enzyme inhibitory activities of the compounds of the present invention and tofacitinib

[0213] Example 4-49 Pharmacodynamic study of the compounds of the present application in a rat rash model induced by targeted therapeutic agents

[0214] A rat rash model was established. Six-week-old female Sprague-Dawley rats were given a targeted therapeutic daily. After several days, a large rash developed on the rats' backs (photos shown in Figure 5). The rash was located in the same area as on the left and right sides, and the severity of the rash was similar on both sides, similar to the condition seen in humans. Therefore, rats are an excellent animal model for simulating rash induced by targeted therapeutics.

[0215] Experiment on the rat animal model to verify the effect of topical ointment of the compound of the present application on preventing rash caused by small molecule targeted therapeutic agents

[0216] After SD rats were acclimated for one week (about 200 g), they were divided into groups of 10. The hair on the back of the rats was shaved clean with an electric razor the day before the experiment, and then the drug administration experiment was carried out. The targeted therapeutic agent was dissolved in a suitable solvent, and all rats were gavage / injected. The mode of administration and dosage are shown in Table 3. The experiment was divided into a drug administration group and a control group. After the rats were given the targeted therapeutic agent, the compound ointment of the present application (concentration as shown in Table 4, about 0.5 g) was applied to the back (about 3 cm * 3 cm) of the rats in the drug administration group; the corresponding blank ointment (about 0.5 g) was applied to the back (about 3 cm * 3 cm) of the rats in the control group; after the application of the medicine, the rats were fixed with a fixing cylinder for about 4 hours, the rats were released after 4 hours, and the residual medicine in the application site was wiped off with clean water, and the rats were returned to the cage for normal feeding.

[0217] The dosing frequency of the targeted therapeutic agent is shown in Table 4. The compound ointment of the present application and the blank ointment were applied once daily. The targeted therapeutic agent and ointment application experiment was repeated daily until a clear rash appeared in the control group. At this time, the number of rats in the treatment group with a lower rash grade than the control group was calculated as the number of rats with effective rash inhibition.

[0218] Table 4 lists the animal experimental combinations of various targeted therapeutic agents and the compound ointment of the present application, as well as the corresponding experimental results (wherein, the value in the relative relief rate column = the number of rats in the treatment group whose rash was lower than that in the control group / the total number of rats in the treatment group × 100%).

[0219] Table 4: Experimental conditions and experimental results of Examples 4-28

[0220] Figure 6 shows photos of the left side, back and right side of typical rats in the control group and the drug-treated group shown in Table 4. Figure 7 shows the rash grade results of some drug-treated groups and the control group at the end of the experiment.

[0221] From the results in Table 4 and Figures 6-7, it can be seen that the compound ointment of the present application can effectively prevent the rash caused by small molecule targeted therapeutic agents.

[0222] Experiment on the rat animal model to verify the effect of topical ointment of the compound of the present application on preventing rash caused by antibody-based targeted therapeutic agents

[0223] After SD rats were acclimated for one week (about 200 g), they were divided into 10 rats per group. The hair on the back of the rats was shaved clean with an electric razor the day before the experiment, and then the drug administration test was carried out. The experiment was divided into a drug administration group and a control group. The frequency, dosage and injection speed of antibody targeted therapeutic agents are shown in Table 5. During the experiment, the drug administration group applied the compound ointment of the present application to the back of the rats (about 3 cm * 3 cm) every day, and the control group applied the corresponding blank ointment (about 0.5 g) to the back of the rats (about 3 cm * 3 cm). After applying the medicine, the rats were fixed with a fixing cylinder for 4 hours. After 4 hours, the rats were released and the residual medicine in the application site was wiped off with clean water, and then returned to the mouse cage for normal feeding. The compound ointment and blank ointment of the present application were applied once a day until obvious rash appeared in the control group. The number of rats whose rash grade in the drug administration group was lower than that in the control group at the end of the statistical experiment was calculated as the number of rats that effectively inhibited the rash.

[0224] Table 5 lists the animal experimental combinations of various antibody targeted therapeutic agents and the compound ointment of the present application, as well as the corresponding experimental results (wherein, the value in the relative relief rate column = the number of rats in the treatment group whose rash level was lower than that in the control group / the total number of rats in the treatment group × 100%).

[0225] Table 5: Experimental conditions and results of Examples 29-31

[0226] FIG8 shows the rash grades of the drug-treated group and the control group at the end of the experiment.

[0227] From the results in Table 4 and FIG8 , it can be seen that the compound ointment of the present application can effectively prevent the rash caused by antibody-based targeted therapeutic agents.

[0228] Experimental study on the rat animal model to verify the topical ointment of the compound of the present application for treating rash caused by small molecule targeted therapeutic agents

[0229] After SD rats were acclimated for one week (about 200 g), they were divided into 10 groups. The hair on the back of the rats was shaved clean with an electric razor the day before the experiment, and then the drug administration experiment was carried out. The targeted therapeutic agent was dissolved in a suitable solvent and all rats were gavage / injected. The mode of administration and dosage were as shown in Table 5. The drug administration experiment was continued every day until all rats showed symptoms of rash, at which time the treatment experiment was started. The experiment was divided into a drug administration group and a control group. After the rats were given the targeted therapeutic agent, the compound ointment of the present application (concentration as shown in Table 5, about 0.5 g) was applied to the back (about 3 cm * 3 cm) of the drug administration group rats; the corresponding blank ointment (about 0.5 g) was applied to the back (about 3 cm * 3 cm) of the control group rats; after the application, the rats were fixed with a fixing cylinder for about 4 hours, the rats were released after 4 hours, and the residual drugs in the application site were wiped off with clean water, and the rats were returned to the cage for normal feeding.

[0230] The dosing frequency of the targeted therapeutic agent is shown in Table 6. The compound of the present application and the blank ointment were applied once daily. The targeted therapeutic agent and ointment application experiments were repeated daily. The number of rats with a lower rash grade in the treatment group than in the control group at the end of the experiment was calculated as the number of rats with effective rash inhibition.

[0231] Table 6 lists the animal experimental combinations of various targeted therapeutic agents and the compound ointment of the present application, as well as the corresponding experimental results (wherein, the value in the relative relief rate column = the number of rats in the treatment group whose rash level was lower than that in the control group / the total number of rats in the treatment group × 100%).

[0232] Table 6: Experimental conditions and results of Examples 32-45

[0233] FIG9 shows the rash grade results of the control group and the drug-treated group at the end of the experiment.

[0234] From the results in Table 6 and FIG9 , it can be seen that the topical ointment of the compound of the present application can effectively treat rashes caused by small molecule targeted therapeutic agents.

[0235] Experimental study on the rat animal model to verify the topical ointment of the compound of the present application for treating rash caused by antibody-based targeted therapeutic agents

[0236] After the SD rats were acclimated for one week (about 200g), they were divided into groups of 10. The hair on the back of the rats was shaved clean with an electric razor the day before the experiment, and then the drug administration test was carried out. The frequency, dosage and injection speed of antibody targeted therapeutic agents are shown in Table 7; the drug was administered continuously for 2 to 3 weeks until all rats showed symptoms of rash, at which time the treatment experiment was started. The experiment was divided into a drug administration group and a control group. After the rats were given antibody targeted therapeutic agents, the compound ointment of the present application (concentration as shown in Table 6, about 0.5g) was applied to the backs (about 3cm*3cm) of the rats in the drug administration group; the corresponding blank ointment (about 0.5g) was applied to the backs (about 3cm*3cm) of the rats in the control group; after applying the medicine, the rats were fixed with a fixing tube for about 4 hours, and the rats were released after 4 hours, and the residual medicine on the application site was wiped off with clean water, and the rats were returned to the cage for normal feeding.

[0237] The antibody targeted therapeutic agent and compound ointment / blank ointment application experiment was repeated, and the number of rats in the treatment group whose rash grade was lower than that of the control group at the end of the experiment was calculated as the number of rats with effectively treated rash.

[0238] Table 7 lists the animal experimental combinations of various antibody targeted therapeutic agents and the compound ointment of the present application, as well as the corresponding experimental results (wherein, the value in the relative relief rate column = the number of rats in the treatment group whose rash level was lower than that in the control group / the total number of rats in the treatment group × 100%).

[0239] Table 7: Experimental conditions and results of Examples 46-49

[0240] FIG10 shows the rash grade results of the drug-treated group and the control group at the end of the experiment.

[0241] It can be seen from Table 7 and Figure 10 that the compound ointment of the present application can effectively treat rashes caused by antibody-based targeted therapeutic agents.

[0242] Example 50 Pharmacodynamics of the Compounds of the Present Application in a Mouse Skin Contact Delayed-Type Hypersensitivity Test After Topical Administration

[0243] Mouse delayed-type hypersensitivity (DTH) is considered an effective model for clinical contact dermatitis and other T-lymphocyte-mediated skin immune diseases, such as atopic dermatitis, alopecia areata, and psoriasis. Mouse DTH shares several common features with these skin immune diseases, including immune infiltration, accompanied by increased inflammatory cytokines, and excessive proliferation of keratinocytes.

[0244] On day 0 and day 1, Balb / c mice were sensitized by locally administering the antigen dinitrofluorobenzene (DNFB) to the back of the mice depilated. On the 5th day, the thickness of the ear was measured using an engineering micrometer, recorded and used as baseline ear thickness. The two ears of the animal were then locally administered a total of 20 μL of 0.2% concentration DNFB (10 μL given to the inner auricle and 10 μL given to the outer auricle) for attack. 24-72 hours after the attack, the ear thickness was measured again as the experimental endpoint ear thickness. During the entire sensitization period and the attack period (-1 day to the 7th day) or before the attack or during the entire attack period (usually the 4th day to the 7th day), the compound topical ointment of the present application was evenly applied to the front and back sides of the right ear for treatment, and the blank ointment was evenly applied to the front and back sides of the left ear, and the swelling degree and swelling rate were calculated.

[0245] Swelling degree = unilateral ear thickness at the end point - baseline ipsilateral thickness; Swelling rate = swelling degree / baseline ear thickness * 100%

[0246] A reduction of 20% or more in ear swelling rate on the compound ointment side compared to the blank ointment side is considered to be effective relief.

[0247] Table 8: Results of the delayed-type hypersensitivity reaction experiment on mice treated with the compounds of the present application.

[0248] From the results in Table 8, it can be seen that different concentrations of the compound ointment of the present application can reduce ear swelling, indicating that topical application of the compound ointment of the present application can effectively alleviate delayed-type hypersensitivity reactions induced by skin contact in mice.

[0249] Mouse ear tissue was formalin-fixed and paraffin-embedded to prepare ear sections. Analysis of ear skin pathology and inflammatory cell infiltration revealed that the epidermis of the ear tissues treated with the blank ointment exhibited varying degrees of atopic dermatitis-related pathological changes, including stromal cell proliferation, thickening, and inflammatory cell infiltration. These symptoms were alleviated in the ear tissues treated with the compound ointment, with a significant reduction in inflammatory cell infiltration. This further demonstrates that topical application of the compound of this application can effectively alleviate delayed-type hypersensitivity reactions in mice.

[0250] Example 51: Pharmacokinetic study of the compound of the present application in human plasma

[0251] Test compound and control working solutions: Dilute 5 μL of compound and control (except propantheline bromide) stock solutions (10 mM in dimethyl sulfoxide (DMSO)) with 495 μL DMSO (working solution concentration: 100 μM, 100% DMSO). Propantheline bromide working solution: Dilute 5 μL of propantheline bromide stock solution (10 mM in dimethyl sulfoxide (DMSO)) with 495 μL H2O (working solution concentration: 100 μM, 1% DMSO)

[0252] The mixed frozen plasma was thawed in a 37°C water bath before the experiment. The plasma was centrifuged at 4000 rpm for 5 minutes and any clots were removed. Using the Apricot automated workstation, 98 μL / well of blank plasma was added to all 96-well reaction plates. (Blank, T0 and T120). 2 μL / well working solution (100 μM) was added to all reaction plates except the blank using the Apricot automated workstation. All reaction plates containing the compound and plasma mixture were incubated in a 37°C water bath. The reaction plates were incubated at 37°C and a timer was started. At the end of the incubation, 400 μL of stop solution (200 ng / mL tolbutamide and 200 ng / mL labetalol in acetonitrile) was added to precipitate the protein. Mix thoroughly. Each plate was sealed and shaken for 20 minutes. After shaking, each plate was centrifuged at 4000 rpm and 4°C for 20 minutes. After centrifugation, 50 μL of supernatant was transferred to 100 μL of HPLC water using the Apricot automated workstation. Each bioassay plate was sealed and shaken for 10 min prior to LC-MS / MS analysis.

[0253] The drug retention or production rate of the test compound after incubation in plasma was calculated using the following equation:

[0254] Drug retention or generation rate (%) = 100 x (drug response at specified incubation time / drug response at T0) where drug is the peak area ratio of analyte to internal standard (IS) and the specified incubation time points are T0 (0 minutes), T120 (120 minutes) and T20 (120 minutes).

[0255] Table 9: Pharmacokinetic results of the compounds of the present application in human plasma

[0256] From the above results, it can be seen that Compound A can be converted into the JAK kinase inhibitor tofacitinib in plasma.

[0257] Example 52: Solubility study of the compounds of the present application

[0258] First, 10 mg of sample was added to 0.2 mL of the corresponding solvent and shaken in a Whatman bottle at room temperature for 24 hours before sampling. UV detection was used and calibration was performed using a three-point standard curve (1, 20, and 200 micromolar). Solubility was calculated by concentration conversion.

[0259] Table 10: Solubility of the compounds of the present application

[0260] From the above results, it can be seen that the water solubility and fat solubility of tofacitinib are very low, while Compound A has better water solubility and fat solubility than tofacitinib, providing a better design space for the design of drug formulations.

[0261] Example 53: Pharmacokinetic study of the compounds of the present application in skin

[0262] Human-specific skin S9 fraction (final protein concentration 1 mg / mL), 0.1 M phosphate buffer, pH 7.4, and test compound (final substrate concentration 1 μM; final dimethyl sulfoxide (DMSO) concentration 0.25%) were pre-incubated at 37°C, followed by the addition of NADPH (final concentration 1 mM), UDPGA (final concentration 1 mM), and aragnetide (final concentration 25 μg / mg) to initiate the reaction. For each compound tested, a no-cofactor control incubation was included, in which 0.1 M phosphate buffer, pH 7.4, was added instead of the cofactor (omitting NADPH and UDPGA). Each test compound was incubated in duplicate, with a separate control incubation. A positive control was incubated with the test compound to assess metabolic activity. This was based on the appearance of the expected metabolites.

[0263] Each compound was incubated for 0, 10, 20, 40, 60, and 120 minutes. A control (no cofactor) was incubated for only 120 minutes. At the appropriate time points, the reaction was stopped by transferring the incubation to acetonitrile (1:3 ratio). The plate was centrifuged at 3,000 rpm at 4°C for 20 minutes to precipitate the protein.

[0264] After protein precipitation, internal standards were added and samples were analyzed using defined LC·MS / MS conditions. Compound A (parent) and tofacitinib (metabolite) were quantified using a matched matrix standard curve.

[0265] From the graph of the peak area ratio (compound peak area / internal standard peak area) over time, determine the gradient of the line. The peak area ratio after detection is converted to the concentration. The results are as follows

[0266] Table 11 Pharmacokinetic study results of the compounds of the present application

[0267] From the above results, it can be seen that Compound A can be converted into the JAK kinase inhibitor tofacitinib in the skin.

[0268] Example 54: Chemical stability study of the compounds of the present application

[0269] After the compound is sealed, it is placed in a constant temperature box at 60 degrees for 30 days. After sampling, the total impurity ratio of the compound is tested by high performance liquid chromatography (calculated by area normalization method).

[0270] Table 12 Chemical stability study results of the compounds of this application

Claims

1. A compound of formula (I) having the structural formula:

2. The compound of formula (I) according to claim 1, which includes a crystalline form, a pharmaceutically acceptable salt, a biologically active metabolite, a solvate, a hydrate, a racemate, an enantiomer or a stereoisomer of the compound of formula (I).

3. Form A of the compound of formula (I), In the X-ray powder diffraction pattern obtained using Cu-Kα radiation and represented by a diffraction angle 2θ, the crystalline form A shows characteristic peaks at 2θ angles of 8.2±0.2° and 11.3±0.2°.

4. The crystalline form A of the compound of formula (I) according to claim 3, which also shows a characteristic peak at at least one of the 2θ angles of 6.8±0.2°, 15.7±0.2°, 17.0±0.2°, 17.6±0.2°, 19.6±0.2°, 20.6±0.2°, 21.2±0.2°, 23.9±0.2° and 24.7±0.2°.

5. Form A of the compound of formula (I), It has an endothermic peak at 120.7±1°C.

6. Form B of the compound of formula (I), In the X-ray powder diffraction pattern obtained using Cu-Kα radiation and represented by a diffraction angle 2θ, the crystal form B shows characteristic peaks at 2θ angles of 7.0±0.2°, 7.8±0.2° and 21.1±0.2°.

7. The crystalline form B of the compound of formula (I) according to claim 6, which also shows a characteristic peak at at least one of the 2θ angles of 14.0±0.2°, 11.2±0.2°, 19.6±0.2°, 17.5±0.2°, 28.2±0.2°, 20.5±0.2°, 26.2±0.2°, 20.9±0.2° and 19.8±0.2°.

8. Form B of the compound of formula (I), It has endothermic peaks at 95.1±1°C and 113.4±1°C.

9. A pharmaceutical composition comprising a compound of formula (I) as described in claim 1 or 2, a crystalline form A of a compound of formula (I) as described in any one of claims 3 to 5, or a crystalline form B of a compound of formula (I) as described in any one of claims 6 to 8, and optionally a pharmaceutically acceptable carrier.

10. Use of the compound of formula (I) according to claim 1 or 2, the crystalline form A of the compound of formula (I) according to any one of claims 3 to 5, the crystalline form B of the compound of formula (I) according to any one of claims 6 to 8, or the pharmaceutical composition according to claim 9 as a JAK inhibitor prodrug.

11. The use according to claim 10, wherein the JAK inhibitor is tofacitinib.

12. Use of the compound of formula (I) according to claim 1 or 2, the crystalline form A of the compound of formula (I) according to any one of claims 3 to 5, the crystalline form B of the compound of formula (I) according to any one of claims 6 to 8, or the pharmaceutical composition according to claim 9 in the preparation of a drug for preventing and / or treating a disease and / or condition.

13. The use according to claim 12, wherein the disease and / or condition comprises a disease or condition associated with the administration of an anti-tumor agent in a subject.

14. The use according to claim 13, wherein the disease or disorder associated with the administration of an anti-tumor agent comprises a rash associated with the administration of an anti-tumor agent.

15. The use according to claim 12, wherein the disease or disorder comprises a skin disease or disorder and / or a subcutaneous tissue disease or disorder.

16. The use according to claim 15, wherein the skin disease or disorder comprises an immune skin disease or disorder.

17. The use according to any one of claims 15-16, wherein the skin disease or condition comprises atopic dermatitis, alopecia areata or psoriasis.

18. The use according to any one of claims 12 to 17, wherein the administration form of the drug comprises a cream, a lotion, a gel, an ointment, an salve, a spray, a liposome preparation, a wipe and / or an aerosol.

19. The use according to any one of claims 12 to 18, wherein the medicament further comprises one or more other active ingredients.

20. A method for preventing and / or treating a disease and / or condition, comprising administering to a subject in need thereof a compound of formula (I) as described in claim 1 or 2, a crystalline form A of a compound of formula (I) as described in any one of claims 3 to 5, a crystalline form B of a compound of formula (I) as described in any one of claims 6 to 8, or a pharmaceutical composition as described in claim 9.

21. The method of claim 20, wherein the disease and / or condition comprises a disease or condition associated with administration of an anti-tumor agent in the subject.

22. The method of claim 21, wherein the disease or condition associated with administration of an anti-tumor agent comprises a rash associated with administration of an anti-tumor agent.

23. The method of claim 20, wherein the disease and / or condition comprises a skin disease or condition and / or a subcutaneous tissue disease or condition.

24. The method of claim 23, wherein the skin disease or disorder comprises an immune skin disease or disorder.

25. The method of any one of claims 23-24, wherein the skin disease or condition comprises atopic dermatitis, alopecia areata, or psoriasis.

26. A pharmaceutical combination or kit comprising: 1) Anti-tumor agents; And 2) the compound of formula (I) as described in claim 1 or 2, the crystalline form A of the compound of formula (I) as described in any one of claims 3-5, the crystalline form B of the compound of formula (I) as described in any one of claims 6-8, or the pharmaceutical composition as described in claim 9.

27. The pharmaceutical combination or kit according to claim 26, further comprising a buffer.

28. The pharmaceutical combination or kit according to any one of claims 26-27, further comprising an excipient.

29. The pharmaceutical combination or kit according to any one of claims 26 to 28, wherein said component 1) and said component 2) are not mixed with each other.

Citation Information

Patent Citations

  • Method for preventing or treating disease or condition associated with antitumor agent

    WO2022143628A1

  • Method for preventing or treating side effects related to EGFR dysfunctions

    WO2022143630A1

  • Compound and use thereof

    WO2023155905A1